{"title":"Comparative evaluation of carvedilol and pitavastatin for antihyperlipidemic activity in tyloxapol-induced hyperlipidemia in Wistar rats","authors":"Md. Akbar , Hasan Ali , Md. Azizur Rahman","doi":"10.1016/j.ipha.2023.11.009","DOIUrl":null,"url":null,"abstract":"<div><p>Aim of the study was designed to investigate the antihyperlipidemic activity of carvedilol and pitavastatin in tyloxapol-induced hyperlipidemia in Wistar rats. The rats were randomly divided into 6 groups. The vehicle control group-I received 2 mL of normal saline for eight days. The pathological control group-II received tyloxapol (400 mg/kg) on 8th day. The treated group-III received 10 mg/kg carvedilol and group-IV received 20 mg/kg carvedilol for eight days and tyloxapol (400 mg/kg) on the 8th day. The group-V received pitavastatin (0.3 mg/kg) for eight days and tyloxapol (400 mg/kg) on the 8th day. The group-VI received carvedilol (20 mg/kg) only for eight days. After eight days of treatment, triglycerides, total cholesterol, high-density lipoprotein, very low-density lipoprotein, thiobarbituric acid reactive substances, and glutathione were estimated in the serum and myocardial tissues along with DNA fragmentation of the liver tissue using gel-electrophoresis. Oral administration of carvedilol to tyloxapol-induced hyperlipidemic rats normalized the changes in the above parameters in a dose dependent manner. Hence, carvedilol with pitavastatin has antihyperlipidemic activity in tyloxapol-induced hyperlipidemia in Wistar rats.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X23001235/pdfft?md5=8b316c7007423929357be787f7e0c207&pid=1-s2.0-S2949866X23001235-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Intelligent Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949866X23001235","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Aim of the study was designed to investigate the antihyperlipidemic activity of carvedilol and pitavastatin in tyloxapol-induced hyperlipidemia in Wistar rats. The rats were randomly divided into 6 groups. The vehicle control group-I received 2 mL of normal saline for eight days. The pathological control group-II received tyloxapol (400 mg/kg) on 8th day. The treated group-III received 10 mg/kg carvedilol and group-IV received 20 mg/kg carvedilol for eight days and tyloxapol (400 mg/kg) on the 8th day. The group-V received pitavastatin (0.3 mg/kg) for eight days and tyloxapol (400 mg/kg) on the 8th day. The group-VI received carvedilol (20 mg/kg) only for eight days. After eight days of treatment, triglycerides, total cholesterol, high-density lipoprotein, very low-density lipoprotein, thiobarbituric acid reactive substances, and glutathione were estimated in the serum and myocardial tissues along with DNA fragmentation of the liver tissue using gel-electrophoresis. Oral administration of carvedilol to tyloxapol-induced hyperlipidemic rats normalized the changes in the above parameters in a dose dependent manner. Hence, carvedilol with pitavastatin has antihyperlipidemic activity in tyloxapol-induced hyperlipidemia in Wistar rats.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
